arrow
Y

Yuki Matsubara

National Cancer Center Hospital East
H指数:11
被引数:476

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer

CLDN18.2阳性胃癌患者接受含zolbetuximab化疗期间早期胃炎的特征分析

2025-09-300
OAAI
Impact of claudin 18.2 expression on treatment outcomes of first-line immunochemotherapy in patients with HER2-negative, proficient MMR, PD-L1 CPS ⩾1 metastatic gastric/gastroesophageal junction cancer

Claudin 18.2 表达对 HER2 阴性、 proficient MMR、PD-L1 CPS ⩾1 转移性胃/胃食管结合部癌患者一线免疫化疗治疗结局的影响

2025-09-200
OA
Ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum-based chemotherapy: A multicenter observational retrospective study (WJOG13420G)

含Ramucirumab的化疗方案用于对铂类为基础的化疗方案耐药/不耐受的胃肠道神经内分泌癌患者的疗效:一项多中心观察性回顾研究(WJOG13420G)

2025-07-230
OAAI
Optimal Primary Prophylaxis for Febrile Neutropenia During Neoadjuvant Cisplatin and 5-Fluorouracil Plus Docetaxel for Esophageal Cancer: A Retrospective Cohort Study

奥沙利铂和5-氟尿嘧啶联合多西他赛新辅助治疗食管癌期间发热性中性粒细胞减少症的最佳一级预防:一项回顾性队列研究

2025-04-240
OAAI
The efficacy and safety of FOLFOX therapy for advanced esophageal squamous cell carcinoma

FOLFOX治疗晚期食管鳞癌的疗效和安全性

2025-03-070
OAAI
Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancer

曲妥珠单抗deruxtecan治疗HER2-positive胃癌或胃食管交界处癌的疗效和安全性的预后和预测因素

2024-11-020
OAAI